Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Search Results
8 results
Filters applied: . Clear all
Results are displayed in a computed author sort order.
The Results By Year timeline is not available.
Page 1
Efficacy of histology-agnostic and molecularly-driven HER2 inhibitors for refractory cancers.
Oncotarget. 2018 Jan 12;9(11):9741-9750. doi: 10.18632/oncotarget.24188. eCollection 2018 Feb 9.
Oncotarget. 2018.
PMID: 29515767
Free PMC article.
Human epidermal receptor family inhibitors in patients with ERBB3 mutated cancers: Entering the back door.
Verlingue L, Hollebecque A, Lacroix L, Postel-Vinay S, Varga A, El Dakdouki Y, Baldini C, Balheda R, Gazzah A, Michot JM, Marabelle A, Mir O, Arnedos M, Rouleau E, Solary E, De Baere T, Angevin E, Armand JP, Michiels S, André F, Deutsch E, Scoazec JY, Soria JC, Massard C.
Verlingue L, et al. Among authors: balheda r.
Eur J Cancer. 2018 Mar;92:1-10. doi: 10.1016/j.ejca.2017.12.020. Epub 2018 Feb 3.
Eur J Cancer. 2018.
PMID: 29413684
Item in Clipboard
Outcomes and prognostic factors for relapsed or refractory lymphoma patients in phase I clinical trials.
Michot JM, Benajiba L, Faivre L, Baldini C, Haddag L, Bonnet C, Massard C, Bigot F, Bigenwald C, Verret B, Thomas ZAP, Varga A, Gazzah A, Hollebecque A, Ghez D, Lazarovici J, Balheda R, Jeanson A, Postel-Vinay S, Danu A, Soria JC, Paoletti X, Ribrag V.
Michot JM, et al. Among authors: balheda r.
Invest New Drugs. 2018 Feb;36(1):62-74. doi: 10.1007/s10637-017-0480-x. Epub 2017 Jun 9.
Invest New Drugs. 2018.
PMID: 28597151
Clinical Trial.
Item in Clipboard
Prognostic factors and outcome of patients with hematological malignancies in phase I trials: the Gustave Roussy scoring system.
Benajiba L, Michot JM, Baldini C, Faivre L, Varga A, Balheda R, Gazzah A, Ileana E, Postel-Vinay S, Massard C, de Botton S, Soria JC, Ribrag V.
Benajiba L, et al. Among authors: balheda r.
Anticancer Drugs. 2017 Jun;28(5):540-545. doi: 10.1097/CAD.0000000000000487.
Anticancer Drugs. 2017.
PMID: 28225458
Item in Clipboard
Tumor growth rate is an early indicator of antitumor drug activity in phase I clinical trials.
Ferté C, Fernandez M, Hollebecque A, Koscielny S, Levy A, Massard C, Balheda R, Bot B, Gomez-Roca C, Dromain C, Ammari S, Soria JC.
Ferté C, et al. Among authors: balheda r.
Clin Cancer Res. 2014 Jan 1;20(1):246-52. doi: 10.1158/1078-0432.CCR-13-2098. Epub 2013 Nov 15.
Clin Cancer Res. 2014.
PMID: 24240109
Free PMC article.
Item in Clipboard
A first in man, phase I dose-escalation study of PHA-793887, an inhibitor of multiple cyclin-dependent kinases (CDK2, 1 and 4) reveals unexpected hepatotoxicity in patients with solid tumors.
Massard C, Soria JC, Anthoney DA, Proctor A, Scaburri A, Pacciarini MA, Laffranchi B, Pellizzoni C, Kroemer G, Armand JP, Balheda R, Twelves CJ.
Massard C, et al. Among authors: balheda r.
Cell Cycle. 2011 Mar 15;10(6):963-70. doi: 10.4161/cc.10.6.15075. Epub 2011 Mar 15.
Cell Cycle. 2011.
PMID: 21368575
Clinical Trial.
Item in Clipboard
Frequency and management of troponin I elevation in patients treated with molecular targeted therapies in phase I trials.
Ederhy S, Massard C, Dufaitre G, Balheda R, Meuleman C, Rocca CG, Izzedine H, Cohen A, Soria JC.
Ederhy S, et al. Among authors: balheda r.
Invest New Drugs. 2012 Apr;30(2):611-5. doi: 10.1007/s10637-010-9546-8. Epub 2010 Oct 6.
Invest New Drugs. 2012.
PMID: 20924643
Clinical Trial.
Item in Clipboard
Rhinitis and epistaxis in patients treated by anti-angiogenic therapy.
Prulière-Escabasse V, Escudier E, Balheda R, Soria JC, Coste A, Massard C.
Prulière-Escabasse V, et al. Among authors: balheda r.
Invest New Drugs. 2009 Jun;27(3):285-6. doi: 10.1007/s10637-008-9168-6. Epub 2008 Aug 27.
Invest New Drugs. 2009.
PMID: 18754078
Item in Clipboard
Cite
Cite